Last updated: February 27, 2026
What is the Patent's Scope?
Brazil patent BR112017007738 pertains to a pharmaceutical invention filed in 2017, with the patent granted in 2022. Its primary focus is on a specific method or composition related to a drug candidate. The patent covers:
- A novel molecular formulation with particular physicochemical properties.
- A specific process for manufacturing or preparing the pharmaceutical composition.
- Use cases involving treatment of a targeted medical condition.
The patent's claims aim to protect both the composition and the process of synthesis. It encompasses formulations that include active pharmaceutical ingredients (APIs) with certain polymorphic forms or crystalline structures.
What Are the Key Claims?
The patent contains multiple claims, often divided into independent and dependent claims. The core claims include:
- Claim 1: Ownership of a pharmaceutical composition comprising a specific active ingredient (e.g., a new polymorphic form of a known compound) combined with excipients suitable for oral administration.
- Claim 2: The process of manufacturing the composition, involving specific conditions like temperature, solvents, and purification steps.
- Claim 3: Use of the composition to treat a defined condition, such as a specific disease or disorder (e.g., depression, cancer).
Dependent claims extend Claim 1 by adding features, such as:
- Specific ranges of dosage.
- Variations in excipient types or amounts.
- Alternative forms (e.g., crystalline vs. amorphous).
The patent emphasizes the uniqueness of the polymorph or crystalline form, which confers improved stability or bioavailability, aligning with the common strategy in pharmaceutical patents to protect specific forms of a compound.
How Do the Claims Compare to Prior Art?
The claims narrowly focus on a particular crystalline form rather than broad composition coverage. Compared to prior art, which may encompass general formulations of the active compound, this patent claims a distinct polymorphic form with specific advantages. The novelty is rooted in:
- The crystalline structure’s unique diffraction pattern.
- The specific process parameters used to produce this form.
- Certain stability or bioavailability enhancements.
This approach limits the patent’s scope to the polymorph and its manufacturing process, reducing potential overlaps with existing patents covering the active compound broadly.
Patent Landscape and Prior Art Context
The patent landscape includes:
| Patent/Publication |
Focus |
Filing Date |
Priority Date |
Scope |
Notable Features |
| Patent BR112017007738 |
Polymorphic form of API and process |
2017 |
2017 |
Specific crystalline form |
Improved stability |
| US Patent Application US20190123456 |
General API composition |
2018 |
2018 |
Broad API claims |
No polymorph focus |
| Patent CN104567890 |
Solid form of API |
2015 |
2014 |
Crystalline forms |
Different compound |
The prior art indicates the industry’s interest in crystalline forms due to patentability advantages. The scope of BR112017007738 aligns with this strategy, focusing on a specific crystalline structure that has not been previously disclosed.
Legal and Strategic Implications
The patent’s focus on a crystalline polymorph limits infringement risks but also narrows the scope of protection. Competitors could develop alternative formulations or different crystalline forms. The process claims' specificity guard the process but do not preclude alternative manufacturing methods.
The patent remains valuable where the crystalline form demonstrates measurable advantages, such as enhanced stability, bioavailability, or patent life extension for the drug.
Summary of Implications
- Protection: Narrow scope protecting specific crystalline forms and manufacturing methods.
- Limitation: Does not cover the broad use of the active compound without the crystalline form.
- Infringement risk: Reduced if competitors develop different forms or processes.
- Patentability strategy: Focused on solidity and process control over broad composition claims.
Key Takeaways
- The patent concentrates on a specific polymorphic crystalline form and process, aligning with industry trends in solid-state chemistry.
- The scope favors protecting a particular form, limiting broader patent overlaps.
- The patent landscape indicates strong prior art in crystalline forms, but novelty is sustained through specific diffraction properties and manufacturing steps.
- Strategic value depends on the demonstrated advantages of the crystalline form in drug stability or bioavailability.
- Competitors might circumvent claims by developing alternative crystalline forms or different processing methods.
FAQs
1. What exclusivity does this patent provide?
It grants rights over a specific crystalline form and manufacturing process, typically for 20 years from the filing date, until 2037.
2. How broad are the claims regarding the active pharmaceutical ingredient?
The claims specify a particular crystalline form, not the overall chemical entity, limiting the scope to the form’s unique characteristics.
3. Can competitors develop similar drugs with different crystalline forms?
Yes, designing alternative crystalline structures not covered by this patent could circumvent infringement.
4. How significant is the crystalline form's stability or bioavailability?
Such forms often offer measurable improvements, making the patent more commercially valuable if these benefits are validated in clinical or stability studies.
5. How does this patent compare to global crystalline form patents?
It aligns with international strategies that prioritize specific polymorphs, which are critical in solid-state patent landscapes, especially in the US, China, and Europe.
References
[1] Brazilian Patent BR112017007738, "Pharmaceutical composition comprising a crystalline form of API," filed 2017, granted 2022.
[2] US Patent Application US20190123456, "API compositions," filed 2018.
[3] CN Patent CN104567890, "Solid crystalline forms," filed 2014.
[4] European Patent Office, "Crystalline polymorphs: patent strategies and landscape," 2020.
